Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review. (Q38239596)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119728%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119728%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

0 references

1 reference

P L Barlow

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119728%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

D Porter

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119728%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

language of work or name

English

0 references

publication date

14 August 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119728%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

12 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119728%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

147

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119728%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119728%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

237-248

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119728%20AND%20SRC:MED&resulttype=core&format=json

Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis

12 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Aromatase inhibitors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Obesity and hormone therapy in breast cancer: an unfinished puzzle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Risks and benefits of aromatase inhibitors in postmenopausal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

Individualization of treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3091-7

10.1007/S10549-014-3091-7

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119728%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

12 March 2020

1010441412

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119728%20AND%20SRC:MED&resulttype=core&format=json